Inventiva shares rise 21.5% in one month and move above their MM50
The Burgundy-based biotech company continues the rebound that began at the end of October, in a Paris market that is barely trending. The stock ranks among the top performers in the index after a pause at the end of last week.
A rebound that brings the stock back above its short-term averages
The Inventiva share gains 1.77% to €3.45 in intraday trading, among the strongest gainers in the SBF 120, while the index rises 0.1%. The stock now trades 3.9% above its MM20 (€3.32) and 8.5% above its MM50 (€3.18), extending a 21.7% gain over one month.
The MM200, at €4.05, remains nearly 15% above the share price and recalls the scale of the 11.1% decline over three months. The RSI at 55 remains neutral.
A consolidated cash position, but no revenue in the first half
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
When it published its H1 2026 results on 29 July, the company reported no revenue for the half-year, compared with €4.5 million a year earlier. It also indicated that its cash covered its requirements until the end of the second quarter of 2027, following an equity offering of €103 million and a €75 million financing transaction announced on 2 June.
Inventiva is listed on two markets: ordinary shares in Paris and ADSs on Nasdaq, with one ADS representing one share. The next scheduled event is the publication of third-quarter 2026 revenue, planned for 23 November.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 0 millions d'euros
Quarterly revenue: 0 millions d'euros
Revenue growth: -100 %
Net income: -69,5 millions d'euros
Free cash flow: -48,7 millions d'euros
Risks mentioned
La trésorerie actuelle ne couvre pas les besoins opérationnels des 12 prochains mois.
Horizon de trésorerie limité à la fin du deuxième trimestre 2027 sans financements additionnels.
Aucun chiffre d'affaires enregistré au premier semestre 2026, contre 4,5 M€ un an plus tôt.
Opportunities identified
Offre Equity de 103 M€ et Opération de Financement de 75 M€ annoncées le 2 juin 2026.
Tranche C de l'Opération de Financement pouvant apporter jusqu'à 20,0 M€.
Exercice des warrants Tranche 3 pouvant générer jusqu'à 116,0 M€.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.